DOCSLIB.ORG

Sametz: CHEM 321 Fall 2012 Organic Chemistry Final

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sametz: CHEM 321 Fall 2012 Organic Chemistry Final Name:_____________________________________ W (Print your name clearly!) Sametz: CHEM 321 Fall 2012 Organic Chemistry Final All answers should be written CLEARLY in the space provided. (If it’s not clear, it’s wrong). You may raise your hand to ask a question if you are unsure what a question is asking of you. 1. (4 points) Give a proper IUPAC name for 2. (4 points) Draw the structure of (1R, 2R)- the following compound: 1,2-cyclobutanediol. 3. (6 points) Rank the following compounds on order of increasing basicity (1 = most basic, 7 = least). 4. (11 points) Draw all possible isomers of C5H11Br, including stereoisomers. Label any stereogenic centers on your structures with an asterisk (*). Note: points will be deducted for incorrect or redundant structures. 5. (4 points) Explain why methane and tetrachloromethane are nonpolar molecules, but dichloromethane is polar. 6. Compound A reacts with base to give epoxide B, whereas compound C (a diastereomer of A) reacts under the same conditions to give D instead. a) (12 points) Give mechanisms for both reactions, and explain why the two diastereomers react differently. Hint: cyclohexanes! 6b) (4 points) Actually, compound D on the previous page is not the final product. Under the reaction conditions, it is in equilibrium with another, highly favoured, form. Draw the structure of the major form, and give a mechanism for its formation under these basic conditions. 7. (8 points) For each of the following pairs of structures, indicate if they represent a pair of diastereomers, enantiomers, constitutional isomers, or identical compounds. a) b) c) d) 8. For the compound shown below: a) (1 point) What is the name for this class of compounds (i.e. 1,2-dienes)? __________________ b) (4 points) Draw a 3-dimensional representation of this structure that reflects its geometry. On this structure, show how the p-orbitals overlap to form -bonds. c) (3 points) Indicate the hybridization of each carbon atom on the molecule. d) (2 points) Explain why the molecule is chiral. 9. For reactions where more than one product is possible: a) (2 points) What is meant by the “thermodynamic product”? b) (2 points) What is meant by the “kinetic product”? c) (3 points) Give three ways to encourage formation of a kinetic product over formation of a competing thermodynamic product. 10. (8 points) An unknown compound containing only carbon and hydrogen, in contact with a platinum catalyst, reacts with 3 equivalents of hydrogen gas to give 1-isopropyl-4- methylcyclohexane. When the unknown compound is treated with ozone followed by dimethylsulfide, the following products are obtained: What is the structure of the unknown product? The structure of 1-isopropyl-4- methylcyclohexane is worth partial credit. 11. (28 points) Give the major organic product(s) for the following reactions, including stereochemistry if applicable. a) b) c) d) e) f) g) 12. (18 points) Provide reagents that will effect the following transformations: a) b) c) d) e) f) 13. (16 points) Reaction mechanisms (8 points): Show a reasonable reaction mechanism for TWO of the following three reactions. If you show work on more than two, CLEARLY indicate which ones you wish to count for credit; otherwise, the grader will choose the first two. a) b) c) (Extra space for question 13) 14. (4 points) Multistep Synthesis: Choose ONE of the two following two synthesis problems below. Show how you can make the final product from the given starting material. The syntheses will require more than one chemical step. Retrosynthetic analysis is worth part credit, but for full credit write out the forward sequence of reactions with specific reagents. Mechanisms are not required and are not graded. If you show work on more than one problem, CLEARLY indicate which you want graded; otherwise the first on the page, as judged by the grader, will count for credit. a) b) 15. (6 points) Multistep Synthesis: Choose ONE of the two following two synthesis problems below. Show how you can make the final product from the given starting material. The syntheses will require more than one chemical step. Retrosynthetic analysis is worth part credit, but for full credit write out the forward sequence of reactions with specific reagents. Mechanisms are not required and are not graded. If you show work on more than one problem, CLEARLY indicate which you want graded; otherwise the first on the page, as judged by the grader, will count for credit. a) b) EXTRA CREDIT: 20 points. The following questions involve the chemistry of phenylethylamines, a class of compounds known for their stimulant and psychoactive effects. 16. The structures of ephedrine and pseudoephedrine are shown below. Only the commercially-used enantiomer of each shown below. Ephedrine is a bronchodilator, and has also been used as a stimulant and weight-loss aid. Pseudoephedrine has found use as a decongestant, but in recent years has been phased out. Both have been used as precursors in the illicit synthesis of methamphetamine, and are controlled substances a) (4 points) Label each stereocenter in the above structures with their correct IUPAC stereochemical descriptor (R or S). b) (4 points) Redraw the structures above as Fischer projections, using the templates below: 17. Not all methamphetamine is treated the same by law. The d-enantiomer (dextromethamphetamine) is a stimulant and psychoactive drug, and a Schedule II controlled substance. The l-enantiomer (levomethamphetamine) is a vasoconstrictor, and is an ingredient in over-the-counter medications such as Vicks VapoInhaler®. The “street drug” may either be a racemate, or pure dextromethamphetamine, depending on the manner of production. a) (4 points) If d-methamphetamine is also the S-isomer, then draw the structure of levomethamphetamine with the correct stereochemistry. b) (2 points) Is the illicit enantiomer (-)-methamphetamine, or (+)-methamphetamine? 18. (6 points) Epinephrine (adrenaline) and norepinephrine (noradrenaline) are hormones and neurotransmitters. You are probably familiar with adrenaline for its involvement in the “fight or flight” response to stress or fear. The biosynthesis of these compounds involves conversion of tyrosine (an amino acid) to L-DOPA (used to treat Parkinson’s disease), then to dopamine (which is involved in reward-seeking and addictive behaviors), then norepinephrine. The final step of the biosynthesis of epinephrine is shown below: Give an arrow-pushing mechanism for this reaction. You may abbreviate the above chemical structures using generic groups such as R, as long as your answer is clear. .
Load more

Recommended publications
  • House Bill No. 2191
    SECOND REGULAR SESSION HOUSE BILL NO. 2191 99TH GENERAL ASSEMBLY INTRODUCED BY REPRESENTATIVE QUADE. 5582H.01I D. ADAM CRUMBLISS, Chief Clerk AN ACT To repeal section 579.060, RSMo, and to enact in lieu thereof one new section relating to controlled substances, with penalty provisions. Be it enacted by the General Assembly of the state of Missouri, as follows: Section A. Section 579.060, RSMo, is repealed and one new section enacted in lieu 2 thereof, to be known as section 579.060, to read as follows: 579.060. 1. A person commits the offense of unlawful sale, distribution, or purchase of 2 over-the-counter methamphetamine precursor drugs if he or she knowingly: 3 (1) Sells, distributes, dispenses, or otherwise provides any number of packages of any 4 drug product containing detectable amounts of ephedrine, levomethamphetamine, 5 phenylpropanolamine, propylhexedrine, or pseudoephedrine, or any of their salts, optical 6 isomers, or salts of optical isomers, in a total amount greater than nine grams to the same 7 individual within a thirty-day period, unless the amount is dispensed, sold, or distributed 8 pursuant to a valid prescription; or 9 (2) Purchases, receives, or otherwise acquires within a thirty-day period any number of 10 packages of any drug product containing any detectable amount of ephedrine, 11 levomethamphetamine, phenylpropanolamine, propylhexedrine, or pseudoephedrine, or any 12 of their salts or optical isomers, or salts of optical isomers in a total amount greater than nine 13 grams, without regard to the number of transactions, unless the amount is purchased, received, 14 or acquired pursuant to a valid prescription; or 15 (3) Purchases, receives, or otherwise acquires within a twenty-four-hour period any 16 number of packages of any drug product containing any detectable amount of ephedrine, 17 levomethamphetamine, phenylpropanolamine, propylhexedrine, or pseudoephedrine, or any EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • Whoexpertcommittee Ondrugdependence
    Thisreportcontainsthecollectiveviewsof an international groupof expertsanddoesnotnecessarilyrepresentthedecisions Tile World 1lealth Organization is a specialized agcncyof the United Nations with orthestatedpolicyof theWorldHealthOrganization primary responsibility for international health'matters anti public health. Through this organization, which was created in 1948, the health professions of' some I65 countries exchange their knowledge and experience with the aim of making possible will permit them lo lead a socially and ccommlically productive lil_. WHOExpertCommittee By means of direct technical cooperation whh its Membcr Stales, and by stimt,- hhensiveding suchhealthcooperationservices, tamonghe preventionthem, WllOprornotesthcdevclopmcntorcomprc-anti control of diseascs, thc improvement o[ environmental conditions, tile development of health manpower, the coordination onDrugDependence anti development of biomedical and health services research, and thc planning and implementation of health programmes. These broad fiekls of endeavour encompass a wide variety of activities, such as developing systems of primary health cltre that reach the whole population of Mem- ber countries; promoting tile health of`mothers and children; combating malnutrition; controlling malaria and other communicable diseases including tuberculosis and leprosy; having achieved tile eradication or smallpox, promoting mass immunization against a numbcr of other preventable diseases; improving mental health; providing safe water supplies: anti training health
    [Show full text]
  • Chiral Separation of Methamphetamine and Amphetamine on an Agilent Infinitylab Poroshell 120 Chiral-V Column with Detection by LC/MS
    Application Note Clinical Research Chiral separation of methamphetamine and amphetamine on an Agilent InfinityLab Poroshell 120 Chiral-V column with detection by LC/MS Authors Abstract Carl Griffin and William Long An Agilent InfinityLab Poroshell 120 Chiral-V 2.1 × 150 mm, 2.7 μm column Agilent Technologies, Inc. (p/n 683775-604) was used to analyze methamphetamine and amphetamine Wilmington, DE, USA by LC/MS, using a mobile phase of methanol with 0.1 % acetic acid and 0.02 % ammonium hydroxide. The analysis was accomplished in 5 minutes, with a resolution Rs of 1.9 or better for racemic amphetamine and methamphetamine. Introduction H NH Experimental N 2 Superficially porous particle columns are An Agilent 1290 Infinity LC system CH3 a popular tool in liquid chromatography. with an Agilent 6460 triple quadrupole Superficially porous particle columns (S)-(+)-Methamphetamine (S)-(+)-Amphetamine LC/MS was used in this experiment. The generate high efficiency at lower Dextromethamphetamine Dextroamphetamine system was modified from its standard pressure relative to their totally porous configuration to have low system volume 1 particle column counterparts . This is H NH and dispersion. Table 1 shows the primarily due to a shorter mass transfer N 2 instrument configuration details. Table 1 distance and substantially narrower CH lists the Agilent InfinityLab Poroshell 120 particle size distribution of the particles 3 Chiral-V 2.1 × 150 mm, 2.7 μm column in the column2. The current trend with (R)-(–)-Methamphetamine (R)-(–)-Amphetamine used in this work. Table 2 shows the LC superficially porous particles is reducing Levomethamphetamine Levoamphetamine and MS parameters.
    [Show full text]
  • Ecstasy/MDMA
    Ecstasy/MDMA What Is Ecstasy/MDMA? MDMA acts as both a stimulant and psychedelic, producing an energizing effect, distortions in time and perception, and enhanced enjoyment of tactile experiences. Adolescents and young adults use it to reduce inhibitions and to promote: • Euphoria • Feelings of closeness • Empathy • Sexuality Although MDMA is known among users as ecstasy, researchers have determined that many ecstasy tablets contain not only MDMA but also a number of other drugs or drug combinations that can be harmful, such as: • Methamphetamine • Ecstasy/MDMA acts as both a • Ketamine stimulant and psychedelic, • producing an energizing effect, Cocaine distortions in time and perception, • The over-the-counter cough suppressant dextromethorphan (DXM) and enhanced enjoyment of tactile • The diet drug ephedrine experiences. • Caffeine • Many ecstasy tablets contain a In addition, other drugs similar to MDMA, such as MDA or PMA, are often sold as ecstasy, number of other drugs or drug combinations that can be harmful. which can lead to overdose and death when the user takes additional doses to obtain the desired effect. • MDMA can cause unwanted psychological effects such as What Are Common Street Names? confusion, anxiety, depression, paranoia, sleep problems, and drug Common street names include: craving. Adam, Beans, Clarity, Disco Biscuit, E, Ecstasy, Eve, Go, Hug Drug, Lover’s Speed, MDMA, • High doses of MDMA can interfere Peace, STP, X, and XTC with the body’s ability to regulate temperature and can result in a What Does It Look Like? sharp increase in body temperature MDMA is mainly distributed in tablet form. MDMA tablets are sold with logos, creating leading to liver, kidney, and cardiovascular failure.
    [Show full text]
  • Amphetamines
    Received: 8 May 2020 Revised: 19 June 2020 Accepted: 6 July 2020 DOI: 10.1002/bdr2.1774 TERATOGEN UPDATE Teratogen update: Amphetamines Joan D. Garey1 | Shari I. Lusskin1,2,3 | Anthony R. Scialli1 1Reproductive Toxicology Center, A Non- Profit Foundation, Washington, District of Abstract Columbia, USA Amphetamines are synthetic noncatecholamine sympathomimetic amines that 2Department of Psychiatry, Icahn School act as psychostimulants. They have been prescribed for the treatment of of Medicine at Mount Sinai, New York, attention-deficit/hyperactivity disorder (ADHD), narcolepsy, and additional New York, USA health conditions. Amphetamines are also drugs of abuse. Some experimental 3Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of animal studies suggested adverse developmental effects of amphetamines, Medicine at Mount Sinai, New York, including structural malformations. These effects were most often observed in New York, USA experimental animals at higher dose levels than those used for treatment or Correspondence abuse and at dose levels that produce maternal toxicity. Controlled studies of Joan D. Garey, Reproductive Toxicology amphetamine use for the treatment of ADHD and other indications did not Center, A Non-Profit Foundation, 2737 Devonshire Pl NW, #120, Washington, suggest that amphetamines are likely to cause structural malformations, DC 20008-3459. although there are three studies associating medication for ADHD or metham- Email: [email protected] phetamine abuse with gastroschisis. We did not locate studies on the neuro- Funding information behavioral effects of prenatal exposures to therapeutic amphetamine use. Reproductive Toxicology Center, A Non- Amphetamine abuse was associated with offspring neurobehavioral abnormal- Profit Foundation ities, but lack of adequate adjustment for confounding interferes with interpre- tation of the associations.
    [Show full text]
  • Testing for Amphetamine and Methamphetamine Abuse Using
    Healthcare & Life Sciences Accurate Biological Testing for Amphetamine and Methamphetamine Abuse Using Chiral HPLC and MS Detection In this study, optimized methods are presented for sample preparation and chiral chromatography for the LC/MS analysis of amphetamine and methamphetamine enantiomers in urine. Introduction from several tens to several hundreds of milligrams, depending on Methamphetamine and amphetamine, powerful CNS stimulants the purity and the isomeric composition, and will metabolize to 3 that have a variety of ethical uses, have side effects of increased amphetamine and 4-hydroxymethamphetamine. Amphetamine confidence, sociability, and energy that have resulted in their metabolizes mainly to 1-phenyl-2-propanone, with smaller extensive abuse as recreational psychoactive drugs. This extends to amounts of 4-hydroxyamphetamine. However, since up to 54% their abuse in sports because of the additional properties of increased of methamphetamine is excreted unchanged and 10-23% as mental alertness and suppression of fatigue.1 Negative side effects amphetamine following oral ingestion, it is usually the parent drug 1 include hypertension and tachycardia. In the usually uncontrolled that is monitored. situations of drug abuse, they exhibit similar psychoactive Culpability for the illicit use of amphetamine and methamphetamine effects, although amphetamine is generally less potent than rests on the ability to distinguish the contribution to the measured methamphetamine. abused product from possible alternative sources of the L-enantiomer. Illicit use of these drugs continues to be high. Public Health Therefore, the separation of the enantiomers is a more accurate England recently reported that the number of people stating their approach for testing. A chiral method can also be used to indicate main injecting drug to be amphetamines and amphetamine-type the synthetic route that was used by the illegal source, which can be substances (such as mephedrone) nearly tripled between 2002 and useful as part of a criminal investigation.
    [Show full text]
  • Public Comment on Synthetic Cathinones, Tetrahydrocannabinol (THC), and Synthetic Cannabinoids Dear Judge Pryor
    FEDERAL DEFENDER SENTENCING GUIDELINES COMMITTEE Lyric Office Centre 440 Louisiana Street, Suite 1350 Houston, Texas 77002-1634 Chair: Marjorie Meyers Phone: 713.718.4600 October 26, 2017 Honorable William H. Pryor, Jr. Acting Chair United States Sentencing Commission One Columbus Circle, N.E. Suite 2-500, South Lobby Washington, D.C. 20002-8002 Re: Public Comment on Synthetic Cathinones, Tetrahydrocannabinol (THC), and Synthetic Cannabinoids Dear Judge Pryor: Synthetic cathinones and cannabinoids are “understudied substances.”1 Not enough information is available about these substances at this time for the Commission to make informed and just guideline amendments to address these drugs either individually or as a class. A far better approach is to amend Note 6 to give courts meaningful guidance on determining which of the listed substances are most similar to the unlisted substance. Specifically, we recommend guidance that will focus courts on the relative potency or impotency of unlisted substances and on medical and public health evidence of direct harms of the different drugs. With this approach, over time, courts and researchers will study these substances in a way that may, at some point, provide enough information for the Commission to specifically address them in the guidelines. We recognize the strong urge to do something to address the harms from synthetic drugs. And we share it. Unfortunately, amending the guidelines to specifically address these synthetic substances individually or as a class will not deter their production, sale, or use. As discussed below, despite a strong belief by many that we can stop people from certain actions by lengthening the threatened punishment, the research shows that lengthening punishment does not deter.
    [Show full text]
  • Medications to Be Avoided Or Used with Caution in Parkinson's Disease
    Medications To Be Avoided Or Used With Caution in Parkinson’s Disease This medication list is not intended to be complete and additional brand names may be found for each medication. Every patient is different and you may need to take one of these medications despite caution against it. Please discuss your particular situation with your physician and do not stop any medication that you are currently taking without first seeking advice from your physician. Most medications should be tapered off and not stopped suddenly. Although you may not be taking these medications at home, one of these medications may be introduced while hospitalized. If a hospitalization is planned, please have your neurologist contact your treating physician in the hospital to advise which medications should be avoided. Medications to be avoided or used with caution in combination with Selegiline HCL (Eldepryl®, Deprenyl®, Zelapar®), Rasagiline (Azilect®) and Safinamide (Xadago®) Medication Type Medication Name Brand Name Narcotics/Analgesics Meperidine Demerol® Tramadol Ultram® Methadone Dolophine® Propoxyphene Darvon® Antidepressants St. John’s Wort Several Brands Muscle Relaxants Cyclobenzaprine Flexeril® Cough Suppressants Dextromethorphan Robitussin® products, other brands — found as an ingredient in various cough and cold medications Decongestants/Stimulants Pseudoephedrine Sudafed® products, other Phenylephrine brands — found as an ingredient Ephedrine in various cold and allergy medications Other medications Linezolid (antibiotic) Zyvox® that inhibit Monoamine oxidase Phenelzine Nardil® Tranylcypromine Parnate® Isocarboxazid Marplan® Note: Additional medications are cautioned against in people taking Monoamine oxidase inhibitors (MAOI), including other opioids (beyond what is mentioned in the chart above), most classes of antidepressants and other stimulants (beyond what is mentioned in the chart above).
    [Show full text]
  • State Methamphetamine Precursor Control Policies
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: From Policy to Practice: State Methamphetamine Precursor Control Policies Author: Jean O’Connor, J.D., M.P.H.; Jamie Chriqui, Ph.D., M.H.S.; Duane McBride, Ph.D.; Shelby Smith Eidson, J.D.; Carissa Baker; Yvonne Terry-McElrath, M.S.; Curt VanderWaal, Ph.D. Document No.: 228133 Date Received: August 2009 Award Number: 2005-IJ-CX-0028 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. From Policy to Practice: State Methamphetamine Precursor Control Policies A report on state methamphetamine laws and regulations, effective October 1, 2005 Prepared by: Jean O’Connor, J.D., M.P.H.1 Jamie Chriqui, Ph.D., M.H.S.1 Duane McBride, Ph.D.2 Shelby Smith Eidson, J.D.1 Carissa Baker1 Yvonne Terry-McElrath, M.S.3 Curt VanderWaal, Ph.D. 2 1The MayaTech Corporation 2Andrews University 3University of Michigan March 2, 2007 This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S.
    [Show full text]